TIPS with lenvatinib and immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cancer that has spread into the main vein of the liver (this is called main trunk portal vein tumor thrombus).
- This spread must be causing increased pressure in the liver (portal hypertension) and may have caused bleeding from veins in the esophagus or stomach.
- Your cancer can have up to 5 small spots elsewhere in the body, but in no more than 2 organs.
- You must be starting or already taking lenvatinib and a PD-1 inhibitor as your first cancer treatment for this condition.
- Your liver function must be fairly good (Child-Pugh class A or B) and you should be able to do daily activities with little help (ECOG 0 or 2).
- You cannot have had other cancers in the past and must not have had liver cancer come back after earlier treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.